GlassScriptPhysician profile
Jad F Naser
NPI 1831282961
$1,204.55
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $63.04 · 2021: $506 · 2022: $138.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $248.88 | 2019-2021 | |
| Amarin Pharma, INC. | $148.11 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.49 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $102.76 | 2019-2021 | |
| Novo Nordisk INC | $67.48 | 2019-2020 | |
| Amgen INC. | $61.25 | 2019-2021 | |
| Glaxosmithkline, LLC. | $26.66 | 2021 | |
| Boston Scientific Corporation | $23.43 | 2019 | |
| Merck Sharp & Dohme LLC | $18.84 | 2021 | |
| Pfizer INC. | $15.82 | 2021 | |
| Allergan, INC. | $15.79 | 2019 | |
| Lilly USA, LLC | $12.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jad Naser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.